| Literature DB >> 24052816 |
Dina A Bakhotmah1, Reda M Abdul-Rahman, Mohammad S Makki, Mohamed A El-Zahabi, Mansor Suliman.
Abstract
The emerging resistance to antimicrobial drugs demands the synthesis of new remedies for microbial infections. Attempts have been made to prepare new compounds by modifications in the quinolone structure. An important method for the synthesis of new quinolone is using Vilsmeier approach but has its own limitations. The present work aimed to synthesize novel norfloxacin analogues using modified Vilsmeier approach and conduct preliminary investigations for the evaluation of their physicochemical properties, photochemical probe, and antimicrobial effects. In an effort to synthesize norfloxacin analogues, only 7-bromo-6-N-benzyl piperazinyl-4-oxoquinoline-3-carboxylic acid was isolated using Vilsmeier approach at high temperature, where N, N'-bis-(4-fluoro-3-nitrophenyl)-oxalamide and N, N'-bis-(3-chloro-4-fluorophenyl)-malonamide were obtained at low temperature. Correlation results showed that lipophilicity, molecular mass, and electronic factors might influence the activity. The synthesized compounds were evaluated for their antimicrobial effects against important pathogens, for their potential use in the inhibition of vitiligo.Entities:
Year: 2011 PMID: 24052816 PMCID: PMC3767343 DOI: 10.5402/2011/184754
Source DB: PubMed Journal: ISRN Org Chem ISSN: 2090-5149
Scheme 1Norfloxacin modification.
Scheme 2
Scheme 3
Figure 3TG and TGD for compound 12.
Figure 4Suggested decomposition stages for compound 12.
Scheme 4A possible formation of N, N′-bis-Aryl malonamide instead of norfloxacin analogues.
Scheme 5
Figure 2The interaction between compound 12 with CHCl3.
Figure 1FT-IR spectrum of 12 in (a) solid and (b) solution states for compound 12.
Various physicochemical properties of highly bioactive compounds.
| Compd. No. | MIC at 30 | Mol. Mass | Melting point | Solubilityc in water (20°C), | ||||
|
|
|
|
| CHCl3 a | Cyclo-Hexaneb | |||
|
| ||||||||
|
| 6 | 10 | 10 | 8 | 299 | 90 | 87 | 200 |
|
| 6 | 10 | 10 | 9 | 327 | 191 | 186 | 300 |
|
| 6 | 10 | 6 | 10 | 374 | 74 | 70 | 90 |
|
| 6 | 10 | 6 | 9 | 366 | 111 | 107 | 350 |
|
| 15 | 10 | 12 | 12 | 442 | 285 | — | 400 |
| Ny | 6 | 6 | 6 | 6 | — | — | — | — |
| Na | 32 | 30 | 30 | 32 | — | — | — | — |
aCrystals cyclisation from CHCl3; bCrystals cyclisation from cyclohexane; chydrolysis characteristics at pH 5.7 and 9 and at 24°C. The tested compounds have a very low rate of hydrolysis, which is considered stable in suspension concentrations under normal condition.
The preliminary screening of antimicrobial activity of the new synthesized compounds.
| Compounds/DMF 50 | Microorganisms/Inhibition zone (mm) | |||||
|---|---|---|---|---|---|---|
| Gram +ve bacteriaa | Gram − ve bacteriab | Fungic | ||||
|
|
|
|
|
| A.F. | |
|
| 9 | 8 | 8 | 10 | 10 | 6 |
|
| 18 | 16 | 15 | 14 | 10 | 6 |
|
| 16 | 16 | 14 | 14 | 8 | 6 |
|
| 8 | 8 | 7 | 11 | 9 | 6 |
|
| 13 | 11 | 12 | 13 | 9 | 6 |
|
| 15 | 14 | 15 | 13 | 10 | 6 |
|
| 20 | 19 | 18 | 17 | 10 | 10 |
| Ny. | 6 | 6 | 6 | 10 | 10 | 32 |
| Na. | 32 | 30 | 30 | 22 | 6 | 6 |
Ny: nystatin, manufactured by Pasteur Lab., Egypt. NS 100 units (100 μg/disk).
Na: nalidixic acid, 30 μg/disk, Bioanalize, Egypt.
a Bacillus Subtilis (B.S.) and Stphylacoccus Aureus (S.A.); b Escherichia Coli (E.C.) and Klebsiella Pneumonia (K.P.); c Candida Albicans (C.A.) and Aspergillus Funigates (A.F.).
MIC of the active biological compounds towards bacteria.
| Compd. No. | Inhibition Zones ( | |||||||||||
|
|
|
|
| |||||||||
| 50 | 40 | 30 | 50 | 40 | 30 | 50 | 40 | 30 | 50 | 40 | 30 | |
|
| ||||||||||||
|
| 18 | 12 | 6 | 16 | 14 | 10 | 15 | 12 | 10 | 14 | 12 | 8 |
|
| 16 | 14 | 6 | 16 | 12 | 10 | 14 | 13 | 10 | 14 | 11 | 9 |
|
| 13 | 10 | 6 | 11 | 10 | 10 | 12 | 10 | 6 | 13 | 11 | 10 |
|
| 15 | 12 | 6 | 14 | 12 | 10 | 15 | 12 | 6 | 13 | 11 | 9 |
|
| 20 | 18 | 15 | 19 | 16 | 10 | 18 | 16 | 12 | 17 | 14 | 12 |
Preliminary screening using UV (λ366 nm) light, conc. 50 μg/disk.
| Compd. No. | Microorganisms (inhibition zones in mm) | |||||
| +ve bacteria | − ve bacteria | Fungi | ||||
|
|
|
|
|
| A.F. | |
|
| ||||||
|
| 18 | 16 | 15 | 14 | No change | No change |
|
| 18 | 17 | 16 | 18 | No change | No change |
|
| 14 | 14 | 12 | 14 | No change | No change |
|
| 17 | 16 | 17 | 16 | No change | No change |
|
| 24 | 21 | 21 | 21 | No change | No change |